[ARPI] ARPI Inc. Takes on the Global Market with Proprietary Technology
- Name 관리자
- Date 2024-12-24
ARPI Inc. Takes on the Global Market with Proprietary Technology
「Aspiring to Become a Global Leader in Medical AI」
A. ARPI Inc. was established in 2021 and specializes in developing medical AI solutions. Our flagship product, ECG Buddy, has obtained new approval from the Korean Ministry of Food and Drug Safety (MFDS), been designated as a new health technology with evaluation exemption, and has been cited in various academic papers. As a medical AI software device, ECG Buddy is recognized for its quality, technological innovation, performance, and safety. ARPI aims to deliver services that provide tangible benefits to both patients and physicians through AI technology that is Accurate, Robust, Practical, and Innovative.
Q. Please explain the characteristics and advantages of ECG Buddy
「 Enhancing Competitiveness with Innovative Products」
A. ECG Buddy is a medical device that assists in diagnosing arrhythmias through 11 cardiac rhythm classification functions and provides 10 digital biomarkers related to emergencies and cardiac dysfunction. Notably, the STEMI (ST-Elevation Myocardial Infarction) biomarker enables the identification of patients requiring emergency coronary angiography with accuracy comparable to or exceeding that of emergency medicine and cardiology specialists, using only initial 12-lead ECG images. This helps make rapid decisions regarding procedures and reduces door-to-balloon time, ultimately improving patient outcomes. Additionally, the left ventricular dysfunction biomarker demonstrates higher accuracy compared to traditional NT-proBNP tests, and other emergency biomarkers, such as those for hyperkalemia, are provided with high precision, supporting timely and appropriate interventions. By significantly enhancing accuracy and speed compared to existing medical technologies, ECG Buddy empowers physicians to make faster and more efficient diagnostic and treatment decisions. For patients, it reduces delays in care and delivers better outcomes, thereby contributing to advancing the quality of healthcare.
Q. What are the directions or blue prints for global market and business in future?
「Promoting Global Exports and Expanding into New Markets」
A. Our company has recently obtained MDSAP (Medical Device Single Audit Program) certification, which covers five countries, as well as EN ISO 13485 Quality Management System certification to support our global expansion efforts. We are currently pursuing medical device regulatory approvals in major countries, including the United States, Europe, Taiwan, Indonesia, UAE, and Japan. Moreover, we have received positive market feedback, with requests from countries such as the United Kingdom, Italy, Vietnam, and Nigeria to test our products for research purposes. Notably, we were recently selected for the Mayo Clinic Accelerate Program in the United States, securing opportunities for international clinical trials and establishing a critical foundation for global market expansion. Over the next five years, we aim to introduce our products to various countries, achieve over 500% growth, and solidify our position as a global leader in providing AI diagnostic support solutions.